Výsledky vyhledávání - "T. J. G. Gevers"

Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver disease

Autor: M A, Lantinga, R G L, de Sévaux, T J G, Gevers, W J G, Oyen, J W, de Fijter, D, Soonawala, R, Zietse, M, Salih, N F, Casteleijn, E M, Spithoven, E, Meijer, R T, Gansevoort, J P H, Drenth On Behalf Of The Dipak Consortium

Publikováno v: The Netherlands Journal of Medicine. 76(5):226-234

BACKGROUND: Cyst infection may occur in autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD). Antimicrobial agents often fail to control infection, leading to invasive action. We aimed to identi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::95b3bedaf4f2a97b9b059c9e81b72ec5
https://hdl.handle.net/11370/bc360867-bdb4-4b82-9f52-c49ea5d76ff4

Zobrazit plný text záznamu

Antiviral therapy in chronic hepatitis E: a systematic review

Autor: A. M. Peters van Ton, T. J. G. Gevers, J. P. H. Drenth

Publikováno v: Journal of Viral Hepatitis, 22, 12, pp. 965-73
Journal of Viral Hepatitis, 22, 965-73

Item does not contain fulltext Hepatitis E viral infection can lead to a chronic infection in immunocompromised patients, resulting in progressive liver disease and cirrhosis. Isolated cases have shown that treatment with ribavirin or pegylated inter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c02ea63381832c8b83a62ac7685f65fd
https://hdl.handle.net/2066/152761

Zobrazit plný text záznamu

The long-term outcome of patients with polycystic liver disease treated with lanreotide

Autor: M, Chrispijn, F, Nevens, T J G, Gevers, R, Vanslembrouck, M G H, van Oijen, W, Coudyzer, A L, Hoffmann, H M, Dekker, R A, de Man, L, van Keimpema, J P H, Drenth

Publikováno v: Alimentary pharmacologytherapeutics. 35(2)

Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume.To establish long-term outco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7975e36b65091837d5e7e82a0ac96905
https://pubmed.ncbi.nlm.nih.gov/22111942

Zobrazit plný text záznamu

Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum

Autor: J J M, van Gulick, T J G, Gevers, L, van Keimpema, J P H, Drenth

Publikováno v: The Netherlands journal of medicine. 69(9)

Autosomal dominant polycystic kidney disease (ADPKD) is a multisystem disorder. It is the most common genetic cause of end-stage renal disease. One frequent extra-renal manifestation is hepatic cyst formation. The majority of ADPKD patients develop c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5e236268634e9e98670b2132dcecca24
https://pubmed.ncbi.nlm.nih.gov/21978978

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání